Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity.
about
Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6.Selecting predictive markers for pharmacogenetic traits: tagging vs. data-mining approaches.CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.Pharmacogenetics in diverse ethnic populations--implications for drug discovery and development.New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity.Cytochrome P450 2D6.Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.Cytochrome P450 pharmacogenetics in African populations.Complexities of CYP2D6 gene analysis and interpretation.Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing.CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients.In vitro functional assessment of 22 newly identified CYP2D6 allelic variants in the Chinese population.The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications.Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population.Full-gene haplotypes refine CYP2D6 metabolizer phenotype inferences.Distribution of CYP2C8 and CYP2C9 amino acid substitution alleles in South Indian diabetes patients: A genotypic and computational protein phenotype study.In vivo characterization of CYP2D6*12, *29 and *84 using dextromethorphan as a probe drug: a case report.CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico.Molecular diversity at the CYP2D6 locus in the Mediterranean regionCYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and NicaraguansCYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort
P2860
Q30711413-17546B69-2ECF-42D0-AABA-4EEE2A36B959Q31144232-EA505F5F-8C9B-4EC1-A4C9-FD515B2AC8FDQ34125166-F0209FA3-C413-4C20-97E2-667CA21261DFQ34775319-61548C8D-6D85-4E41-8C16-128DAF1ADD6DQ34994964-99A5F875-4E71-40A7-B9E4-661620BB1B35Q36475190-387B66EC-0D1F-435C-BDEB-D69AA600BE2DQ37178666-9157A3D5-D230-4D87-9724-62C5DB24D03AQ37380190-E096E7D7-52BA-4E9B-AB4A-FD57D9EACEFEQ37513508-CB2FF188-C7B8-479D-B092-6383CAA9BD35Q37964573-5DDA5B41-F677-41B0-A9E4-EEB5B256DA3DQ38099372-A0B86B89-A92E-4D42-BFE7-EBF7428FB31FQ38154914-8E960C9E-D042-47F6-BC0B-07F5E995E33EQ39282325-39FBEFF9-D6EC-4CDA-81BD-BD3C9398B1CBQ40382805-BF68FFB7-3BB1-4D1F-B909-4FAB93647D4EQ41732730-E4617A91-4504-4192-8769-DD4DA1A023F6Q42047832-FDEC9B41-6966-4815-A292-32EB9B45A3A7Q45151691-B0D638DA-4E25-4623-BA8F-3051F971D1D9Q46506742-5B71102E-B467-4DF9-B795-B6090928BB87Q47707268-70391358-424A-4032-95CF-C7A69BE3F06BQ48058245-B3DB44BB-6709-4A8D-8234-7298B459965BQ51099780-E2FD7505-56F1-403D-AD66-A615491EC834Q54605695-EA3C3035-40F8-4075-B8A1-79B7C715846CQ56836892-362904AD-6DD5-46E1-ADD4-91163E3317B8Q57585762-E9323D86-4377-4415-A711-62D4BD321A5AQ58698638-B9762898-E3AA-4B25-B095-3AA62925EEF6
P2860
Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Characterization of the CYP2D6 ...... ng reduced catalytic activity.
@en
Characterization of the CYP2D6 ...... ng reduced catalytic activity.
@nl
type
label
Characterization of the CYP2D6 ...... ng reduced catalytic activity.
@en
Characterization of the CYP2D6 ...... ng reduced catalytic activity.
@nl
prefLabel
Characterization of the CYP2D6 ...... ng reduced catalytic activity.
@en
Characterization of the CYP2D6 ...... ng reduced catalytic activity.
@nl
P2093
P1476
Characterization of the CYP2D6 ...... ng reduced catalytic activity.
@en
P2093
Bertilsson L
Hidestrand M
Johansson I
Wennerholm A
P304
P356
10.1097/00008571-200107000-00005
P577
2001-07-01T00:00:00Z